Vol 27, No 5 (2020)
Editorial Comment
Published online: 2020-11-06

open access

Page views 573
Article views/downloads 653
Get Citation

Connect on Social Media

Connect on Social Media

COVID-19 and its implication for venous thromboembolism

Michał Ciurzynski1, Justyna Domienik-Karłowicz1, Miłosz Jaguszewski2, Piotr Pruszczyk1
DOI: 10.5603/CJ.2020.0153
Pubmed: 33165897
Cardiol J 2020;27(5):481-484.

Abstract

Not available

Article available in PDF format

View PDF Download PDF file

References

  1. He J, Wu Bo, Chen Y, et al. Characteristic Electrocardiographic Manifestations in Patients With COVID-19. Can J Cardiol. 2020; 36(6): 966.e1–966.e4.
  2. Klok FA, Kruip M, van der Meer N, et al. Incidence of thrombotic complications in critically ill ICU patients with COVID-19. Thrombosis Res. 2020; 191: 145–147.
  3. Cui S, Chen S, Li X, et al. Prevalence of venous thromboembolism in patients with severe novel coronavirus pneumonia. J Thromb Haemost. 2020; 18(6): 1421–1424.
  4. Wichmann D, Sperhake JP, Lütgehetmann M, et al. Autopsy Findings and Venous Thromboembolism in Patients With COVID-19: A Prospective Cohort Study. Ann Intern Med. 2020; 173(4): 268–277.
  5. Helms J, Tacquard C, Severac F, et al. High risk of thrombosis in patients with severe SARS-CoV-2 infection: a multicenter prospective cohort study. Intensive Care Med. 2020; 46(6): 1089–1098.
  6. Marone EM, Bonalumi G, Curci R, et al. Characteristics of venous thromboembolism in COVID-19 patients: a multicenter experience from northern italy. Ann Vasc Surg. 2020 [Epub ahead of print].
  7. Tal S, Spectre G, Kornowski R, et al. Venous Thromboembolism Complicated with COVID-19: What Do We Know So Far? Acta Haematol. 2020 [Epub ahead of print]: 1–8.
  8. Guo J, Huang Z, Lin Li, et al. Coronavirus disease 2019 (COVID-19) and cardiovascular disease: a viewpoint on the potential influence of angiotensin-converting enzyme inhibitors/angiotensin receptor blockers on onset and severity of severe acute respiratory syndrome coronavirus 2 infection. J Am Heart Assoc. 2020; 9(7): e016219.
  9. Zhang Y, Xiao M, Zhang S, et al. Coagulopathy and Antiphospholipid Antibodies in Patients with Covid-19. N Engl J Med. 2020; 382(17): e38.
  10. Guan WJ, Ni ZY, Hu Yu, et al. Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med. 2020; 382(18): 1708–1720.
  11. Tang N, Li D, Wang X, et al. Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia. J Thromb Haemost. 2020; 18(4): 844–847.
  12. Konstantinides SV, Meyer G, Becattini C, et al. 2019 ESC Guidelines for the diagnosis and management of acute pulmonary embolism developed in collaboration with the European Respiratory Society (ERS): The Task Force for the diagnosis and management of acute pulmonary embolism of the European Society of Cardiology (ESC). Eur Respir J. 2019; 54(3).
  13. Figliozzi S, Masci PG, Ahmadi N, et al. Predictors of adverse prognosis in COVID-19: A systematic review and meta-analysis. Eur J Clin Invest. 2020 [Epub ahead of print]: e13362.
  14. Kosior DA, Undas A, Kopeć G, et al. Guidance for anticoagulation management in venous thromboembolism during the coronavirus disease 2019 pandemic in Poland: an expert opinion of the Section on Pulmonary Circulation of the Polish Cardiac Society. Kardiol Pol. 2020; 78(6): 642–646.
  15. Bikdeli B, Madhavan MV, Jimenez D, et al. COVID-19 and Thrombotic or Thromboembolic Disease: Implications for Prevention, Antithrombotic Therapy, and Follow-Up: JACC State-of-the-Art Review. J Am Coll Cardiol. 2020; 75(23): 2950–2973.
  16. Thachil J, Tang N, Gando S, et al. ISTH interim guidance on recognition and management of coagulopathy in COVID-19. J Thromb Haemost. 2020; 18(5): 1023–1026.
  17. Moores LK, Tritschler T, Brosnahan S, et al. Prevention, diagnosis, and treatment of VTE in patients with coronavirus disease 2019: CHEST guideline and expert panel report. Chest. 2020; 158(3): 1143–1163.